Вы находитесь на странице: 1из 9

Half the battle won with new child-friendly TB drugs:

What's the other half?

with new child-friendly TB drugs: What's the other half? CNS Webinar 15 December, 2015 Dr Brenda

CNS Webinar

15 December, 2015

Dr Brenda Waning

Chief, Global Drug Facility (GDF)

What's the other half? CNS Webinar 15 December, 2015 Dr Brenda Waning Chief, Global Drug Facility

The other half: Making sure these medicines get to all those who need them as quickly as possible

What needs to happen:

1.

Increase awareness & demand

2.

Secure financing

3.

Support countries to adopt new medicines

4.

Procure medicines & begin treatment

5.

Manage market supply & demand

to adopt new medicines 4. Procure medicines & begin treatment 5. Manage market supply & demand

2

1. Increase awareness of & demand for the pediatric TB formulations

Target audiences: practitioners, caregivers, advocates, and policy makers at global and national levels

Conduct widespread awareness campaigns to ensure key decision

makers & consumers know these new medicines exist;

Educate key decision makers & consumers on the benefits &

advantages of the new formulations

Garner political will to aggressively treat children: new formulations facilitate treatment; opportunity to reset goals & expectations

Utilize policy levers, where appropriate, to increase demand

Donors & other third-party payors can institute policies that require or encourage countries to switch to new formulations

& other third-party payors can institute policies that require or encourage countries to switch to new

3

2. Secure adequate financing to ensure countries have

funds to purchase the new pedi TB formulations

Advocate for budget space to purchase the new formulations in countries who are funding their national treatment programs;

Support countries who may need to reprogram or reallocate Global

Fund budgets to create fiscal space to purchase these new medicines

Consider increasing targets for pediatric TB treatment; TB Situation Room

Ensure that countries transitioning from Global Fund to domestic financing continue to use these optimized formulations

Secure additional funding to provide grants to countries for the

initial conversion (bridge grants)

formulations • Secure additional funding to provide grants to countries for the initial conversion (bridge grants)

4

3. Support countries to adopt the new pedi TB formulations

Provide technical assistance & capacity building:

Revision of national pediatric TB treatment guidelines

Supply planning on how to optimally phase-out the old products and phase-

in the new products (inventory management, ordering frequency)

Quantification, forecasting, early warning systems

Mechanisms & resources to provide TA & capacity building:

Missions to countries

Partner mobilization

Regional and country workshops and trainings for

national TB treatment programs, partners, consultants

mobilization – Regional and country workshops and trainings for national TB treatment programs, partners, consultants 5
mobilization – Regional and country workshops and trainings for national TB treatment programs, partners, consultants 5

5

4. Procure the medicines and begin treating children

with the new pedi TB formulations

begin treating children with the new pedi TB formulations New Pediatric TB formulations are available for

New Pediatric TB

formulations are available

for purchase via the Global Drug Facility

5. Actively monitor and manage the fragile, pediatric TB medicines market

Establish systems to actively monitor the supply and demand sides of the market

To ensure a consistent, uninterrupted supply of medicines is available in countries;

To ensure medicines are not wasted;

Monitor demand in countries, develop global forecasts, and coordinate production planning with manufacturers

Consolidate demand to the fewest number of formulations

Conduct coordinated or pooled procurement, where possible

Establish pedi TB procurement working group similar to pedi ARV working group

Develop medicines stockpile

Rapid response to emergency orders, reduce lead times, and improve production planning

Identify and attract additional supplier(s) to develop the new formulations

Implement interventions to decrease prices

Monitor & evaluate product introduction

Share challenges, progress with all stakeholders via regular market management meetings

product introduction – Share challenges, progress with all stakeholders via regular market management meetings 7

7

The Global Drug Facility is Uniquely Positioned to

Support New TB Product Introduction

GDF is a Geneva-based initiative of the Stop TB Partnership (2001),

hosted by UNOPS

One-stop shop for TB medicines & diagnostics:

Procurement

First-line drugs (FLDs) since 2001; second-line drugs (SLDs), pediatric

meds, and diagnostics since 2008

Sole supplier of SLDs for the Global Fund

Technical assistance, capacity building

Procurement & supply chain management

Support for new product introduction

Currently supporting bedaquiline introduction

Market management & coordination

product introduction • Currently supporting bedaquiline introduction • Market management & coordination 8

8

Thank You!
Thank You!

Contact Info Brenda Waning:

Chief, Global Drug Facility

brendaw@stoptb.org